(CercleFinance.com) – Degroof Petercam renewed its buy recommendation on Carmat on Thursday, with a target price of 20.2 euros, following annual results deemed ‘unsurprising’.
After a 2022 financial year marked by the resolution of quality problems on its artificial heart, the year 2023 will be that of the recovery of activity, estimates the Belgian investment house in a research note.
According to Degroof, the two main challenges the company is facing today are (1) the take-off of the production necessary to achieve its annual objectives and (2) the extension of its financial visibility beyond July 2023. .
In the short term, it is nevertheless the approval of the FDA for the resumption of the feasibility study in the United States which should constitute the main catalyst for the value, continues the Brussels firm.
Degroof Petercam points out that Carmat has planned to keep the market regularly informed of the progress of its Aeson core, which should allow investors to better understand the dynamics from which the company will benefit this year.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
